Male breast cancer (MBC) comprises less than 1% of all cancers in men and less than 1% of all breast cancer in United States. In contrast to female breast cancer (FBC), male patients are generally older and have more advanced disease. MBC is rarely detected before age 30 and the mean age is 67 years. The advanced stage at presentation of MBC is thought to be related to thin breast parenchymal tissue in men. The tumors are often low or intermediate grade, with a higher percentage of ER-positive tumors. Patients with MBC routinely receive tamoxifen. All-cause mortality (ACM) is higher than FBC: for example in node-positive patients, all-cause mortality rate at 10-year was 67% in MBC versus 52% in FBC. There is a higher rate of distant recurrence for MBC. Factors such as advanced age, stage, visceral metastasis, triple-negative disease, androgen receptor, high grade, never married, smoking and low income at baseline are known to adversely affect outcome. The survival rates for MBC have lagged behind those for FBC. Prognosis may improve with more research on MBC in the future.